Stock Events

Stock Events

Athira Pharma Inc 

$6.75
32
-$0.44-6.12% Friday 21:00

Statistics

Day High
7.35
Day Low
6.63
52W High
8.36
52W Low
2.2
Volume
70,313
Avg. Volume
1,056,070
Mkt Cap
26.62M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-1.8
-1.28
-0.75
-0.23
Expected EPS
-1.6718
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-193.88MNet Income

Analyst Ratings

$10.00Average Price Target
The highest estimate is 10.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ATHA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Biogen is a leading biotech company focusing on neurodegenerative diseases, directly competing with Athira Pharma's focus on Alzheimer's and other neurological disorders.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly has a strong pipeline in Alzheimer's disease treatments, making it a direct competitor to Athira Pharma in the neurodegenerative disease space.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.83B
ACADIA Pharmaceuticals focuses on the development of drugs to treat central nervous system disorders, competing with Athira Pharma in the neurology and psychiatry treatment market.
AnaptysBio
ANAB
Mkt Cap1.02B
AnaptysBio is engaged in developing therapeutic antibodies for the treatment of neuroinflammatory diseases, positioning it as a competitor in the neurodegenerative disease market.
Anavex Life Sciences
AVXL
Mkt Cap684.57M
Anavex Life Sciences Corp. specializes in the development of novel therapeutics for the treatment of Alzheimer's disease, Parkinson's, and other central nervous system diseases.
Prothena
PRTA
Mkt Cap578.67M
Prothena Corporation plc is a biotechnology company focused on the discovery and development of novel therapies for neurodegenerative diseases, including Alzheimer's.
Axsome Therapeutics
AXSM
Mkt Cap6.74B
Axsome Therapeutics, Inc. is developing novel therapies for central nervous system (CNS) disorders, including cognitive disorders related to Alzheimer's disease.
Arbutus Biopharma
ABUS
Mkt Cap906.73M
Arbutus Biopharma Corporation is slightly less directly competitive but is involved in the development of therapies for viral diseases and associated neurodegenerative conditions.

About

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Show more...
CEO
Dr. Mark J. Litton M.B.A., Ph.D.
Employees
26
Country
US
ISIN
US04746L1044

Listings

F
DE
6AI.F
XNAS
US
LONA
XNAS
US
ATHA
BOATS
BOATS
LONA.BOATS

0 Comments

Share your thoughts

FAQ

What is Athira Pharma Inc stock price today?▼
The current price of ATHA is $6.75 USD — it has decreased by -6.12% in the past 24 hours. Watch Athira Pharma Inc stock price performance more closely on the chart.
What is Athira Pharma Inc stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Athira Pharma Inc stocks are traded under the ticker ATHA.
Is Athira Pharma Inc stock price growing?▼
ATHA stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Athira Pharma Inc has showed a +150% increase.
What is Athira Pharma Inc market cap?▼
Today Athira Pharma Inc has the market capitalization of 26.62M
When is the next Athira Pharma Inc earnings date?▼
Athira Pharma Inc is going to release the next earnings report on May 07, 2026.
What were Athira Pharma Inc earnings last quarter?▼
ATHA earnings for the last quarter are -1.68 USD per share, whereas the estimation was -1.06 USD resulting in a -58.49% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Athira Pharma Inc revenue for the last year?▼
Athira Pharma Inc revenue for the last year amounts to 0 USD.
What is Athira Pharma Inc net income for the last year?▼
ATHA net income for the last year is -193.88M USD.
How many employees does Athira Pharma Inc have?▼
As of April 01, 2026, the company has 26 employees.
In which sector is Athira Pharma Inc located?▼
Athira Pharma Inc operates in the Health Care sector.
When did Athira Pharma Inc complete a stock split?▼
The last stock split for Athira Pharma Inc was on September 18, 2025 with a ratio of 1:10.
Where is Athira Pharma Inc headquartered?▼
Athira Pharma Inc is headquartered in Bothell, US.